Introduction: Binaural beat technology (BBT) products are sold internationally as personal development and health improvement tools. Producers suggest benefit from regular listening to binaural beats including reduced stress and anxiety, and increased focus, concentration, motivation, confidence, and depth in meditation. Binaural beats are auditory brainstem responses that originate in the superior olivary nucleus as a result of different frequency auditory stimuli provided to each ear. Listeners to binaural beat “hear” a beat at a frequency equal to the difference between the frequencies of the applied tones. Objectives: The objectives of this pilot study were to gather preliminary data on psychologic and physiologic effects of 60 days daily use of BBT for hypothesis generation and to assess compliance, feasibility, and safety for future studies. Design: Uncontrolled pilot study. Subjects: Eight healthy adults participated in the study. Intervention: Participants listened to a CD with delta (0–4 Hz) binaural beat frequencies daily for 60 days. Outcome Measures: Psychologic and physiological data were collected before and after a 60-day intervention. Psychologic: Depression (Beck Depression Inventory-2), anxiety (State-Trait Anxiety Inventory), mood (Profile of Mood States), absorption (Tellegen Absorption Scale) and quality of Life (World Health Organization-Quality of Life Inventory). Physiological: Cortisol, dehydroepiandrosterone, melatonin, insulin-like growth factor-1, serotonin, dopamine, epinephrine, norepinephrine, weight, blood pressure, high sensitivity C-reactive protein. Results: There was a decrease in trait anxiety (p = 0.004), an increase in quality of life (p = 0.03), and a decrease in insulin-like growth factor-1 (p = 0.01) and dopamine (p = 0.02) observed between pre- and postintervention measurements. Conclusions: Binaural beat technology may exhibit positive effect on self-reported psychologic measures, especially anxiety. Further research is warranted to explore the effects on anxiety using a larger, randomized and controlled trial.

When two auditory stimuli of different frequency are presented to each ear, binaural beats are perceived by the listener. The binaural beat frequency is equal to the difference between the frequencies applied to each ear. Our primary objective was to assess whether steady-state entrainment of electroencephalographic activity to the binaural beat occurs when exposed to a specific binaural beat frequency as has been hypothesized. Our secondary objective was to gather preliminary data on neuropsychologic and physiologic effects of binaural beat technology. A randomized, blinded, placebo-controlled crossover experiment in 4 healthy adult subjects. Subjects were randomized to experimental auditory stimulus of 30 minutes of binaural beat at 7 Hz (carrier frequencies: 133 Hz L; 140 Hz R) with an overlay of pink noise resembling the sound of rain on one session and control stimuli of the same overlay without the binaural beat carrier frequencies on the other session. Data were collected during two separate sessions 1 week apart. Neuropsychologic and blood pressure data were collected before and after the intervention; electroencephalographic data were collected before, during, and after listening to either binaural beats or control. Neuropsychologic measures included State Trait Anxiety Inventory, Profile of Mood States, Rey Auditory Verbal List Test, Stroop Test, and Controlled Oral Word Association Test. Spectral and coherence analysis was performed on the electroencephalogram (EEG), and all measures were analyzed for changes between sessions with and without binaural beat stimuli. There were no significant differences between the experimental and control conditions in any of the EEG measures. There was an increase of the Profile of Mood States depression subscale in the experimental condition relative to the control condition (p = 0.02). There was also a significant decrease in immediate verbal memory recall (p = 0.03) in the experimental condition compared to control condition. We did not find support for steady-state entrainment of the scalp-recorded EEG while listening to 7-Hz binaural beats. Although our data indicated increased depression and poorer immediate recall after listening to binaural beats, larger studies are needed to confirm these findings.

Summary: In different inflammatory disease models, heat‐shock proteins (hsp) and hsp‐derived peptides have been demonstrated to possess anti‐inflammatory properties. While some studies have shown that hsp can directly interact with antigen‐presenting cells, others report that bacterial hsp can induce specific T cells with regulatory phenotypes. Effective characterization of the immunomodulatory effects of hsp 70, however, has historically been confounded by lipopolysaccharide (LPS) contamination. In this study, we compared the effects of LPS‐free Mycobacterial tuberculosis hsp 70 (TBhsp70) and its possible contaminants on dendritic cells (DC). We demonstrate herein that LPS‐free TBhsp70 inhibits murine DC maturation in vitro, while LPS‐contaminated TBhsp70 induces DC maturation. Mock recombinant preparations have no effect. In contrast to LPS, TBhsp70 does not induce tumour necrosis factor‐α production by DC, but interleukin‐10. In vivo, only LPS‐contaminated TBhsp70 induces up‐regulation of CD86 in splenic mature DC. Finally, TBhsp70 inhibited phytohaemagglutinin‐induced T‐cell proliferation. Our results support the hypothesis that TBhsp70 does not have inflammatory potential, but rather has immunosuppressive properties.

Cytokines are key modulators of the immune responses that take place in the inflamed synovium of arthritis patients. Consequently, substances that can reverse the inflammatory profile of the inflamed joint are potential tools for clinical management of the disease. Mycobacterial heat shock protein 70 (MTBHSP70) has been found to protect rats from experimentally induced arthritis through the induction of interleukin (IL)‐10‐producing T cells. In this study, we have demonstrated that MTBHSP70 induces IL‐10 production in synoviocytes from arthritis patients and peripheral blood monoculear cells (PBMCs) from both patients and healthy controls. IL‐10 production was accompanied by a decrease in tumour necrosis factor (TNF)‐α production by synovial cells. Separation studies showed that the target cells were mainly monocytes. Accordingly, we observed that MTBHSP70 delayed maturation of murine bone marrow‐derived dendritic cells. Our results suggest that MTBHSP may act on antigen‐presenting cells (APCs) to modulate the cytokine response in arthritis and support an anti‐inflammatory role for this protein, suggesting that it may be of therapeutic use in the modulation of arthritis.

Oxidative stress and muscle damage occur during exhaustive bouts of exercise, and many runners report pain and soreness as major influences on changes or breaks in training regimens, creating a barrier to training persistence. Methylsulfonylmethane (MSM) is a sulfur-based nutritional supplement that is purported to have pain and inflammation-reducing effects. To investigate the effects of MSM in attenuating damage associated with physical exertion, this randomized, double-blind, placebo-controlled study evaluated the effects of MSM supplementation on exercise-induced pain, oxidative stress and muscle damage. Twenty-two healthy females (n = 17) and males (n = 5) (age 33.7 ± 6.9 yrs.) were recruited from the 2014 Portland Half-Marathon registrant pool. Participants were randomized to take either MSM (OptiMSM®) (n = 11), or a placebo (n = 11) at 3 g/day for 21 days prior to the race and for two days after (23 total). Participants provided blood samples for measurement of markers of oxidative stress, and completed VAS surveys for pain approximately one month prior to the race (T0), and at 15 min (T1), 90 min (T2), 1 Day (T3), and 2 days (T4) after race finish. The primary outcome measure 8-hydroxy-2-deoxyguanine (8-OHdG) measured oxidative stress. Secondary outcomes included malondialdehyde (MDA) for oxidative stress, creatine kinase (CK) and lactate dehydrogenase (LDH) as measures of muscle damage, and muscle (MP) and joint pain (JP) recorded using a 100 mm Visual Analogue Scale (VAS). Data were analyzed using repeated and multivariate ANOVAs, and simple contrasts compared post-race time points to baseline, presented as mean (SD) or mean change (95% CI) where appropriate. Running a half-marathon induced significant increases in all outcome measures (p < 0.001). From baseline, 8-OHdG increased significantly at T1 by 1.53 ng/mL (0.86–2.20 ng/mL CI, p < 0.001) and T2 by 1.19 ng/mL (0.37–2.01 ng/mL CI, p < 0.01), and fell below baseline levels at T3 by −0.46 ng/mL (−1.18–0.26 CI, p > 0.05) and T4 by −0.57 ng/mL (−1.27–0.13 CI, p > 0.05). MDA increased significantly at T1 by 7.3 μM (3.9–10.7 CI, p < 0.001). Muscle damage markers CK and LDH saw significant increases from baseline at all time-points (p < 0.01). Muscle and joint pain increased significantly from baseline at T1, T2, and T3 (p < 0.01) and returned to baseline levels at T4. Time-by-treatment results did not reach statistical significance for any outcome measure, however, the MSM group saw clinically significant (Δ > 10 mm) reductions in both muscle and joint pain. Participation in a half-marathon was associated with increased markers of oxidative stress, muscle damage, and pain. MSM supplementation was not associated with a decrease from pre-training levels of oxidative stress or muscle damage associated with an acute bout of exercise. MSM supplementation attenuated post-exercise muscle and joint pain at clinically, but not statistically significant levels.